VIVUS Announces Scientific Presentations

VIVUS Announces Scientific Presentations

MOUNTAIN VIEW, Calif., June 15, 2013 (GLOBE NEWSWIRE) -- VIVUS,Inc.
(Nasdaq:VVUS), a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity and
sexual health, today announced the following scientific presentations:

Conference

ENDO 2013: The Endocrine Society's 95^th Annual Meeting and Expo

June 15-18, 2013

Moscone Center, San Francisco, CA

Date/Time

Poster Presentation Date: Saturday, June 15^th, 2013, 1:45-3:45pm

Session Location: Expo Hall, Moscone Center

Poster Number: SAT-663

Abstract Number: 3585

Presentation Title

Improvements in Glycemic Parameters Associated With Magnitude of Weight Loss
in Overweight/Obese Subjects Receiving Phentermine and Topiramate
Extended-Release Over 2 Years

Authors: Lawrence J. Cheskin, MD^a; Charles H. Bowden, MD^b

Affiliations:
^aJohns Hopkins Bloomberg School of Public Health, and Johns Hopkins Weight
Management Center, Baltimore, MD
^bVIVUS, Inc., Mountain View, CA

Conference

ESH 2013:23^rd European Meeting on Hypertension and Cardiovascular Protection

June 14-17, 2013

Mico Milano Congressi, Milan, Italy

Date/Time

Oral Presentation Date: Monday, June 17^th, 2013, 9:20-9:30

Session Location: Red Hall, Mico Milano Congressi

Presentation Title

Improvements in Cardiometabolic Parameters as a Function of Magnitude of
Weight Loss in Subjects With Hypertension Treated With Phentermine and
Topiramate Extended-Release (PHEN/TPM ER)

Authors: Samuel Klein, MD^a; Hermann Toplak, MD^b; Roman V. Dvorak, MD, PhD^c

Affiliations:
^aWashington University Medical School, St. Louis, MO, USA
^bMedical University of Graz, Graz, Austria
^cVIVUS, Inc., Mountain View, CA, USA

Conference

ESH 2013:23^rd European Meeting on Hypertension and Cardiovascular Protection

June 14-17, 2013

Mico Milano Congressi, Milan, Italy

Date/Time

Oral Presentation Date: Monday, June 17^th, 2013, 17:50-18:00

Session Location: Blue Hall, Mico Milano Congressi

Presentation Title

Changes in Hypertension Status Associated With Phentermine and Topiramate
Extended-Release Over 108 Weeks

Authors: Jens Jordan, MD^a; Krzysztof Narkiewicz, MD, PhD^b; Wesley W. Day,
PhD^c

Affiliations:
^aInstitute of Clinical Pharmacology, Hannover Medical School, Hannover,
Germany
^bDepartment of Hypertension and Diabetology, Medical University of Gdansk,
Gdansk, Poland
^cVIVUS, Inc., Mountain View, CA, USA

About Qsymia

Qsymia^® (phentermine and topiramate extended-release) capsules CIV is
approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet
and increased physical activity for chronic weight management in adults with
an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or
greater (overweight) in the presence of at least one weight-related medical
condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been
established. The safety and effectiveness of Qsymia in combination with other
products intended for weight loss, including prescription and over-the-counter
drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia^® (phentermine and topiramate extended-release) capsules CIV is
contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism;
in patients receiving treatment or within 14 days following treatment with
monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to
sympathomimetic amines, topiramate, or any of the inactive ingredients in
Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a
negative pregnancy test before treatment and monthly thereafter and use
effective contraception consistently during Qsymia therapy. If a patient
becomes pregnant while taking Qsymia, treatment should be discontinued
immediately, and the patient should be informed of the potential hazard to the
fetus.

The most commonly observed side effects in controlled clinical studies, 5% or
greater and at least 1.5 times placebo, include paraesthesia, dizziness,
dysgeusia, insomnia, constipation, and dry mouth.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity and
sexual health. For more information about the company, please visit
www.vivus.com.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should," among
others. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. VIVUS does
not undertake an obligation to update or revise any forward-looking
statements. Investors should read the risk factors set forth in VIVUS's Form
10-K for the year ending December 31, 2012, as amended by the Form 10-K/A
filed on April 30, 2013 and by the Form 10-K/A filed on June 12, 2013, and
periodic reports filed with the Securities and Exchange Commission.

CONTACT: VIVUS, Inc.
         Dana B. Shinbaum
         Corporate Development
         & Investor Relations
         shinbaum@vivus.com
        
         Investor Relations:
         The Trout Group
         Brian Korb
         bkorb@troutgroup.com
         646-378-2923
 
Press spacebar to pause and continue. Press esc to stop.